US 11,702,411 B2
Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
Jie Jack Li, Redwood City, CA (US); Elena S. Koltun, Redwood City, CA (US); Adrian Liam Gill, Redwood City, CA (US); Andreas Buckl, Redwood City, CA (US); Walter Won, Redwood City, CA (US); Naing Aay, Redwood City, CA (US); Kevin Mellem, Redwood City, CA (US); Christos Tzitzilonis, Redwood City, CA (US); Ashutosh Jogalekar, Redwood City, CA (US); and James Joseph Cregg, Redwood City, CA (US)
Assigned to REVOLUTION MEDICINES, INC., Redwood City, CA (US)
Filed by Revolution Medicines, Inc., Redwood City, CA (US)
Filed on Apr. 10, 2020, as Appl. No. 16/845,539.
Application 16/845,539 is a continuation of application No. PCT/US2018/055502, filed on Oct. 11, 2018.
Claims priority of provisional application 62/571,760, filed on Oct. 12, 2017.
Claims priority of provisional application 62/615,353, filed on Jan. 9, 2018.
Claims priority of provisional application 62/678,889, filed on May 31, 2018.
Prior Publication US 2020/0339552 A1, Oct. 29, 2020
Int. Cl. C07D 407/14 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01)
CPC C07D 407/14 (2013.01) [C07D 401/04 (2013.01); C07D 401/14 (2013.01)] 6 Claims
 
1. A compound, or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, selected from the group consisting of

OG Complex Work Unit Chemistry